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Abstract: Angelman syndrome has been suggested as a disease model of neurogenetic 
developmental condition with a speciﬁ  c behavioral phenotype. It is due to lack of expression 
of the UBE3A gene, an imprinted gene located on chromosome 15q. Here we review the main 
features of this phenotype, characterized by happy demeanor with prominent smiling, poorly 
speciﬁ  c laughing and general exuberance, associated with hypermotor behavior, stereotypies, 
and reduced behavioral adaptive skills despite proactive social contact. All these phenotypic 
characteristics are currently difﬁ  cult to quantify and have been subject to some differences in 
interpretation. For example, prevalence of autistic disorder is still debated. Many of these features 
may occur in other syndromic or nonsyndromic forms of severe intellectual disability, but their 
combination, with particularly prominent laughter and smiling may be speciﬁ  c of Angelman 
syndrome. Management of problematic behaviors is primarily based on behavioral approaches, 
though psychoactive medication (eg, neuroleptics or antidepressants) may be required.
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Over the last few decades, the recognition of behavioral phenotypes has become 
increasingly important in clinical genetics. Behavioral phenotypes have been deﬁ  ned 
as characteristic patterns of motor, cognitive, communicative and social abnormalities 
that are consistently associated with a biological disorder (O’Brien and Yule 1995). 
Being familiar with typical behavioral features as part of manifestations of disease 
has important implications relating to diagnosis, management and research. From a 
diagnostic standpoint, identifying a particular behavioral pattern may be as important 
as recognizing physical dysmorphism. Dykens (1995) suggested that a behavioral 
phenotype represents increased probability that individuals with a given syndrome 
exhibit certain behavioral and developmental features in comparison to those who 
do not present the syndrome. This probabilistic concept of behavioral phenotypes 
accounts for eventual interindividual variability in occurrence, intensity, and timing 
of behavioral features.
For diagnostic purposes, it has been recommended that the observed traits should 
be subjected to assessment using measurable criteria in at least ﬁ  ve different domains, 
namely intellectual functioning, speech and language, attention deﬁ  cits, social impair-
ment, and other behavioral disturbances (eg, self-injury) (McMahon 1999). Evaluation 
of the features must take the individuals’ developmental complexity into account. It 
must be noted that there is wide variation in the availability of tests for assessing these 
different domains. Caution must be taken to avoid restrictive symptom interpretation, 
which might overlook factors such as anxiety, depression or differently qualiﬁ  ed 
behavioral problems that may be difﬁ  cult to recognize but might be amenable to 
effective management.Neuropsychiatric Disease and Treatment 2008:4(3) 578
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As for management, correct identiﬁ  cation of certain 
communication strategies or certain behavioral problems 
should direct the therapeutic approach while avoiding inap-
propriate treatment (Pelc and Dan 2008).
As regards research, the concept of behavioral phenotypes 
has proved to be of great importance for understanding of 
biological and genetic contributions to behavior. Angelman 
syndrome provides an historical and on-going illustration of 
this process. Actually, Harry Angelman (1965) pioneered the 
behavioral phenotype concept by emphasizing a ‘puppet’-like 
behavior as a distinctive feature of the syndrome he described. 
Angelman syndrome manifests itself clinically as a severe 
form of developmental delay including a virtual absence of 
speech and abnormal gait as well as other coordination dif-
ﬁ  culties, an exuberant, contagiously happy demeanor with 
almost constant smiling and prominent laughing, tongue 
protrusion and a seizure disorder (Table 1).
From a behavioral phenotype 
to genetic characterization
Replication and extension of Harry Angelman’s ﬁ  ndings 
(Angelman 1965) in a large number of patients led to the 
detection of chromosome 15q abnormalities in a high propor-
tion of cases (Magenis et al 1987). This discovery led to sub-
sequent identiﬁ  cation of abnormalities speciﬁ  cally affecting 
the chromosome 15 inherited from the mother, while similar 
abnormalities affecting the paternally-inherited are associ-
ated with Prader-Willi syndrome, a clinically distinct condi-
tion (Knoll et al 1989). These two disorders thus illustrate 
the phenomenon of genomic imprinting, where the factor 
determining the phenotypic outcome is the parental origin of 
the chromosome defect, reﬂ  ecting differential expression of 
genes according to their maternal or paternal origin. Angel-
man syndrome and Prader-Willi syndrome thus provided the 
ﬁ  rst example of ‘imprinting mutations’ in humans. Therefore, 
Angelman syndrome has become the clinical archetype of 
this nonmendelian type of inheritance. Based on the same 
assumption of the clinical validity of Angelman syndrome, 
several causative genetic mechanisms were subsequently 
characterized, eventually leading to the identiﬁ  cation of the 
responsibility of loss of UBE3A gene function in inducing 
the syndrome (Kishino et al 1997; Matsuura et al 1997). 
Almost all manifestations of Angelman syndrome seem to 
be related to lack of UBE3A gene expression in the brain. 
In physiological conditions, only the maternal allele is 
expressed in some brain regions. Lack of UBE3A expression 
may result from several mechanisms including deletion of the 
15q11-q13 region of the chromosome 15 inherited from the 
mother (this may be isolated or rarely be due to chromosome 
re-arrangement), paternal uniparental disomy (this may 
occur postzygotically or less often arise through meiotic 
nondisjunction), imprinting defect (this may occasionally 
be due to imprinting center mutation), or UBE3A mutation 
(reviewed in Dan et al 2004a). Because the UBE3A gene is 
known, the characterization of a behavioral phenotype can 
promote insights into the mechanisms by which they arise. 
Such a ‘bottom-up’ line has been suggested for ﬁ  nding the 
molecular determinants that might account for some neu-
rophysiological aspects of the syndrome (Dan et al 2004b). 
However, similar approaches aiming to understand genetic 
mechanisms underlying behavior are likely to be less suc-
cessful, as contributions of single genes to behavior are very 
limited. In contrast, interactions between genes, and between 
genetic and environmental factors are expected to be major. 
Moreover, further methodological improvements are required 
to better characterize the behavioral features that accompany 
the syndrome (Horsler and Oliver 2006b).
Studies of Angelman syndrome 
behavioral phenotype
The behavioral aspects of a large number of patients with 
Angelman syndrome have been reported (eg, Robb et al 
1989; Fryburg et al 1991; Zori et al 1992; Clayton-Smith 
1993; Jolleff and Ryan 1993; Penner et al 1993; Bottani 
et al 1994; Saitoh et al 1994; Buntinx et al 1995; Bürger 
et al 1996; Laan et al 1996; Smith et al 1996; Hou et al 
1997; Buckley et al 1998; Moncla et al 1999; Dan and 
Cheron 2003). This has led to preliminary delineation of 
a constellation of features including prominent laughter, 
hyperactivity, peculiar communication pattern, mouthing 
of objects and motor stereotypies. Systematic studies of 
the behavioral phenotype have conﬁ  rmed or qualiﬁ  ed these 
observations (Summers et al 1995; Summers and Feldman 
1999; Clarke and Marston 2000; Walz and Benson 2002; 
Oliver et al 2002; Didden et al 2004, 2006; Barry et al 2005; 
Horsler and Oliver 2006a; Walz 2006). No clear differences 
have emerged so far between the different molecular classes 
underlying Angelman syndrome (chromosome 15q11-q13 
deletion, uniparental disomy, imprinting defect, or UBE3A 
mutation). The link between genotype and phenotype is yet 
to be clariﬁ  ed.
Happy demeanor
Apparent happy disposition with frequent smiling and 
laughing has been regarded as a hallmark of Angelman 
syndrome since the original description as ‘puppet children’ Neuropsychiatric Disease and Treatment 2008:4(3) 579
Behavior and neuropsychiatric manifestations in Angelman syndrome
(Angelman 1965). It has been reported with great consistency 
in subsequent descriptions. This aspect served to label the 
condition (‘happy puppet syndrome’) for over 15 years, 
before use of the eponym Angelman syndrome was encour-
aged (Williams and Frias 1982). It is included within the 
features of the ‘behavioral uniqueness’ that characterizes 
100% of patients with Angelman syndrome (Williams et al 
2006) (Table 1). In a survey of 64 studies reporting behavioral 
features in a total of 842 patients aged from a few months to 
76 years of age, Horsler and Oliver (2006b) noted than only 
4 studies did not make any reference to laughing, smiling or 
happy demeanor. Some authors proposed that smiling and 
laughing were pathognomonic of the condition (Summers 
et al 1995). In a comparison with other conditions, individu-
als with Angelman syndrome were found to be more likely 
to exhibit cheerful or happy behavior than patients with 
Down syndrome, Prader-Willi syndrome or nonspeciﬁ  c 
mental retardation (Walz and Benson 2002). However, this 
has been questioned by a more recent case-control study, in 
which no difference was found in the prevalence of unpro-
voked laughter between patients with Angelman syndrome 
and control participants with moderate to profound mental 
retardation (Barry et al 2005).
Some authors have suggested that bouts of laughter 
were inappropriate, whether context-inappropriate (eg, 
Kibel and Burness 1973; Dooley et al 1981; Buntinx et al 
1995) or unrelated to context (eg, Berg and Pakula 1972; 
Elian 1975; Cassidy et al 2000; Lossie et al 2001; Rich-
man et al 2006). It has also been suggested that laughter 
was independent of happy or sad environments and not 
associated with any emotional change (Williams and Frias 
1982). In our experience, laughter seems to be very often 
clearly related to context, though it may occur in situations 
that are not thought to be pleasant, such as blood sampling, 
Table 1 Clinical diagnostic criteria for Angelman syndrome (Adapted from Williams et al 2006) 
A. Consistent features (100%)
Developmental delay, functionally severe
Movement or balance disorder, usually ataxia of gait, and/or tremulous movement of limbs. Movement disorder can be mild. May not appear as frank 
ataxia but can be forward lurching, unsteadiness, clumsiness, or quick, jerky motions
Behavioral uniqueness: any combination of frequent laughter/smiling; apparent happy demeanor; easily excitable personality, often with uplifted hand-
ﬂ  apping, or waving movements; hypermotor behavior
Speech impairment, none or minimal use of words; receptive and nonverbal communication skills higher than verbal ones
B. Frequent features (more than 80%)
Delayed, disproportionate growth in head circumference, usually resulting in microcephaly (−2 standard deviations of normal head circumference) by 
age 2 years. Microcephaly is more pronounced in those with 15q11.2-q13 deletions
Seizures, onset usually before 3 years of age. Seizure severity usually decreases with age but the seizure disorder lasts throughout adulthood
Abnormal electroencephalogram, with a characteristic pattern (Dan and Boyd 2003). The electroencephalographic abnormalities can occur in the ﬁ  rst 
2 years of life, can precede clinical features, and are often not correlated to clinical seizure events
C.   Associated features (20%–80%)
Flat occiput
Occipital groove
Protruding tongue
Tongue thrusting; suck/swallowing disorders
Feeding problems and/or truncal hypotonia during infancy
Prognathia
Wide mouth, wide-spaced teeth
Frequent drooling
Excessive chewing/mouthing behaviors
Strabismus
Hypopigmented skin, light hair, and eye color compared to family), seen only in deletion cases
Hyperactive lower extremity deep tendon reﬂ  exes
Uplifted, ﬂ  exed arm position especially during ambulation
Wide-based gait with pronated or valgus-positioned ankles
Increased sensitivity to heat
Abnormal sleep-wake cycles and diminished need for sleep
Attraction to/fascination with water; fascination with crinkly items such as certain papers and plastics
Abnormal food related behaviors
Obesity (in the older child)
Scoliosis
ConstipationNeuropsychiatric Disease and Treatment 2008:4(3) 580
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as noted by others (Kibel and Burness 1973; Dooley et al 
1981; Clayton-Smith 1992). It may increase markedly with 
anxiety and some patients may appear to be in discomfort 
during pervasive bouts of laughter. In the original report, 
Angelman (1965) described that it could often occur as ‘an 
almost convulsive state’ and that ‘spike and wave forms were 
present during the period of laughter’. However, there has 
been no further evidence of gelastic seizures in Angelman 
syndrome (Pelc et al 2008a). Extremely rarely, laughing can 
provoke potentially dangerous syncope (which is amenable 
to pharmacological treatment) (Vanagt et al 2005). More 
often smiling and laughing appear to be appropriate. One 
study speciﬁ  cally addressing this question showed that
three children with Angelman syndrome showed increased 
smiling and laughing in social contexts expressly, contrast-
ing with low levels of smiling and laughing in nonsocial 
situations (Oliver et al 2002). A further study of 11 children 
aged 4 to11 years with a chromosome 15q11-q13 deletion 
showed that smiling and laughing were enhanced in a condi-
tion involving adult speech, touch, smiling, laughing and eye 
contact compared with a condition involving adult speech 
only or adult proximity only (Horsler and Oliver 2006a). 
Laughter may become less frequent with advancing age 
(Buntinx et al 1995; Laan et al 1996). We have seen several 
adolescents and adults who looked miserable for prolonged 
periods; in some cases, this accompanied medical problems 
such as severe gastroesophageal reﬂ  ux.
Hyperactivity, impulsivity, 
and inattention
Hyperactivity has been noted with great consistency (eg, Zori 
et al 1992; Buntinx et al 1995; Hou et al 1997; Summers and 
Feldman 1999; Clarke and Marston 2000; Galván-Manso et al 
2002; Artigas-Pallarés et al 2005). Hypermotor behavior is 
mentioned as part of the ‘behavioral uniqueness’ (Williams 
et al 2006) (Table 1). Philippart and Minassian (2005) sug-
gested that exuberance better describes this behavior. Lower 
hyperactivity/noncompliance scores were found than in 
patients with nonsyndromic developmental disabilities (Sum-
mers and Feldman 1999), Smith-Magenis syndrome (Clarke 
and Marston 2000), or Prader-Willi syndrome (Clarke and 
Marston 2000). In one other study patients with Angelman 
syndrome had higher hyperactivity scores than controls with 
moderate to profound mental retardation (Barry et al 2005). 
Hyperactivity appears to decrease with age (Buntinx et al 1995; 
Clarke and Marston 2000). Clayton-Smith (2001) observed 
that hyperactivity of childhood gave way to reluctance to 
exercise in all 28 adolescents and adults she studied.
Impulsivity is also frequent. However, it is not more 
prevalent than in nonspeciﬁ  c mental retardation and sig-
niﬁ  cantly less prevalent than in Down syndrome (Walz and 
Benson 2002). In one study, impulsivity was signiﬁ  cantly 
less frequent in Angelman syndrome (27%) than in nonspe-
ciﬁ  c moderate to profound mental retardation (60%) (Barry 
et al 2005).
Distractibility and short attention span is frequent but has 
insufﬁ  ciently been studied (Hersh et al 1981; Pulsifer 1996; 
Barry et al 2005). It seems to be comparable with ﬁ  ndings 
in moderate to profound intellectual disability (Barry et al 
2005), though one study documented shorter attention span 
and higher levels of distractibility in Angelman syndrome 
than Down syndrome, Prader-Willi syndrome, or nonspeciﬁ  c 
mental retardation (Walz and Benson 2002). Among other 
factors, attention may be disrupted by seizure activity (Pelc 
et al 2008b). Attention span has been noted to increase with 
age (Clayton-Smith 2001).
Effect of management of problematic hyperactivity, 
impulsivity, and inattention has not been studied in patients 
with Angelman syndrome. Current approaches are mostly 
behavioral.
In some patients, neuroleptic (ie, antipsychotic) medica-
tion may be beneﬁ  cial. Low dose neuroleptics (eg, risperi-
done) may reduce both hyperactivity and impulsivity. Dosage 
varies according to the desired effect and may greatly differ 
from patient to patient. Neuroleptics have no signiﬁ  cant 
positive effects on cognitive or attentional problems but may 
enhance them, particularly at higher doses. They may be 
associated with a number of side effects, including sedation 
and motor effects. In addition, propensity toward weight gain 
may limit the use of risperidone.
Drugs in ‘antidepressant’ classes may be useful in 
some patients. In our experience, tricyclic agents, such 
as amitriptylin, can be effective in reducing hyperactivity 
and impulsivity. They do not seem to improve attention. 
Cholinergic side effects may occur, such as dry mouth 
(which is usually not a problem given the spontaneous 
drooling) and gastrointestinal perturbations, including 
constipation. In a few patients, we found that selective 
serotonin reuptake inhibitors (we used ﬂ  uoxetine) could 
reduce hyperactivity, impulsivity and anxiety. However, in 
one 6 year-old girl with a chromosome 15q11-q13 deletion, 
ﬂ  uoxetine seemed to enhance impulsivity, hyperactivity 
and excitability. Potential interference with sleep quality 
and architecture (Pelc et al 2008b) should be considered. 
The recent development of chronobiotic agents may be 
promising in this respect.Neuropsychiatric Disease and Treatment 2008:4(3) 581
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The effectiveness of psychostimulant drugs, such as 
methylphenidate, has been debated but no sound data are 
available. In our experience, these agents have not been 
useful in controlling behavioral problems or in increas-
ing attention in patients with Angelman syndrome. In one 
personal case (Dan and Boyd 2005), a 7 year-old boy with 
a chromosome 15q11-q13 deletion, methylphenidate pre-
cipitated a state of lethargy associated with generalized fast 
electroencephalographic activity (‘mu rhythm status’).
More recent drugs used in attention deﬁ  cit/hyperactivity 
disorder, such as atomoxetin, have not been evaluated reli-
ably in Angelman syndrome. In this context, it would appear 
particularly important to study medication with expected 
action on mood, anxiety, and attention.
Stereotypies
Stereotyped behaviors, including stereotypies, compulsions, 
and rituals, can be seen. Motor stereotypies are very fre-
quent (Summers et al 1995; Walz 2006). They may be focal 
(eg, head shaking, grimacing, bruxism, ﬁ  nger wiggling) or 
whole-body movements (eg, rocking, jumping, or walking 
back and forth), with rather ﬁ  xed and predictable patterns in 
a given patient. None of these patterns are speciﬁ  c, as they 
frequently occur in other conditions with mental retardation 
or communication disorder, and even sometimes in typically 
developing children.
The most characteristic pattern, mentioned in the clinical 
diagnostic criteria (Williams et al 2006), is hand ﬂ  apping 
and waving. Hand ﬂ  apping was reported in 73% and 74% 
of individuals, respectively, in a study of 68 patients (aged 
1 to 22 years, mean 9.6) (Artigas-Pallarés et al 2005) and a 
study of 340 patients (aged 3 to 22 years, mean 11.0) (Walz 
and Baranek 2006). It must be noted that hand ﬂ  apping is 
frequent in other syndromes (eg, fragile X syndrome) as well 
as nonsyndromic mental retardation and autistic spectrum. 
Furthermore, stereotyped hand ﬂ  apping is not uncommon 
in typically developing infants (Thelen 1979), toddlers and 
even children (Mahone et al 2004). However, in a compara-
tive study of children and adolescents, patients with Angel-
man syndrome were found to engage signiﬁ  cantly more in 
repetitive hand ﬂ  apping than those with Down syndrome, 
Prader-Willi syndrome or nonspeciﬁ  c mental retardation 
(Walz and Benson 2002).
Stereotypies also often involve the mouth, with mouth-
ing or chewing of nonedible objects. Prevalence of eating 
nonfood substances may vary between 5% (Galván-Manso 
et al 2002) and 42% of patients (Barry et al 2005). This 
behavior seems to be more prevalent in Angelman syndrome 
than in other forms of mental retardation (Walz and Benson 
2002).
Occasionally, stereotyped behaviors can have self-
injurious effects, such as mouthing blunt objects or toxic 
substances. Compulsive eye-rubbing, which may become 
prominent in adolescence or adulthood, may result in kera-
toconus.
Stress, excitement, fatigue, or apparent boredom may be 
favoring factors. Stereotypies may be suppressed by distract-
ing the subject. In most individuals, stereotypies do not cause 
discomfort or signiﬁ  cant social impairment. Therefore, no 
treatment is required. When management is indicated, non-
pharmacological approaches appear limited; restrain therapy 
may lead to discomfort. Pharmacological treatment may also 
be limited, both by lack of efﬁ  cacy and adverse effect. Pos-
sible options include risperidone and ﬂ  uoxetine.
Autistic features
In addition to the stereotypies described above, a number of 
characteristic features of Angelman syndrome may be seen 
in the context of the autistic spectrum, including virtual 
absence of speech, impaired use of nonverbal communica-
tive behaviors (facial expression, body postures/gestures to 
regulate social interaction and decoding of emotional facial 
expressions), attention deﬁ  cits, hyperactivity, feeding and 
sleeping problems, and delays in motor development. Autis-
tic features are considered as comorbidity by some authors 
(Williams et al 2001) and as characteristic of the syndrome 
by others. The notion that autistic symptomatology is typical 
(Steffenburg et al 1996) has been disputed (Thompson and 
Bolton 2003). Repetitive sensory and motor behaviors have 
been correlated with a low developmental proﬁ  le rather than 
seen as indicating autism (Bonati et al 2007). Several authors 
have reported a low incidence of autistic features in children 
with Angelman syndrome (Cohen et al 2005; Veltman et al 
2005), emphasizing appropriate social reciprocity (Smith 
et al 1996; Saitoh et al 1994). In two recent studies, a high 
incidence of DSM-IV-based diagnoses of autistic disorder 
was suggested: 10 in 16 (Trillingsgaard and Østergaard 2004) 
and 8 in 19 (Peters et al 2004a). Three other patients in the 
ﬁ  rst study and all the other patients in the second study had 
some autistic-like behaviors, most noticeably stereotyped 
hand or body mannerisms. The discrepancies between the 
different reports may be related in differences in studied 
populations and in study design. However, subjective inter-
pretation of the symptomatology might also be an important 
factor even in studies based on validated evaluation scales. It 
must be stressed that incorrect diagnosis of autistic spectrum Neuropsychiatric Disease and Treatment 2008:4(3) 582
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may result in misinterpretation of behavioral features and in 
overlooking the social and communication potential. This 
may enhance the risk of a self-fulﬁ  lling prophecy.
Social interaction
In contrast to the autistic-like features, the conviviality of 
most patients with Angelman syndrome is particularly strik-
ing. Interest for social interaction seems to be prominent from 
early infancy, when social smiling emerges. Most patients 
are eager to communicate despite the verbal impairment, 
though nonverbal behaviors, such as facial expressions, body 
postures, and gestures regulating social interaction, may lack 
accuracy and be difﬁ  cult to interpret. The ‘happy’ disposi-
tion is accompanied by a markedly positive interpersonal 
bias and social disinhibition, which persists in adulthood. 
Though individuals appear to be almost constantly happy, 
some may have high levels of anxiety. Fear of strangers 
is often diminished but speciﬁ  c phobias may be present. 
Fear of crowds can affect up to half of patients and fear of 
noise up to a third (Artigas-Pallarés et al 2005). Aggressive 
behavior is rare both in children and adults (Hersh et al 1981; 
Zori et al 1992; Summers et al 1995; Clayton-Smith 2001). 
However, despite a tendency toward social gregariousness 
and positive interpersonal bias, patients often encounter 
problems in everyday interaction because of poor detec-
tion and respect of emotional and social signals. Therefore, 
overall social adaptation may be impaired. Management of 
eventual social maladaptiveness is mostly behavioral. Edu-
cational and cultural factors seem to have a major impact on 
social interaction.
Behavioral adaptability
Adaptive behavior skills are generally reduced, being rela-
tively more impaired than social skills. The impairment in 
adaptive skills is mostly due to weakness in cognitive (Peters 
et al 2004b), motor (Dan et al 2001), and communication 
skills (Jolleff et al 2006). Patients have difﬁ  culties in achiev-
ing coordinated psychomotor skills and those required for 
mastering activities of daily living, such as self-help and 
independence in feeding, dressing and toileting. All indi-
viduals require supervision, including as adults. However, 
there is wide variation in self-help skills. Among 28 patients 
(16 females and 12 males) aged between 16 and 40 years, 
21 were able to walk, 20 could feed themselves, 14 could 
dress and undress provided the fastenings on the clothes 
were simple, all required assistance with washing, 20 had 
day-time sphincter control while 3 had night-time sphincter 
control, 7 could carry out simple household tasks, most were 
able to make simple choices and indicate likes and dislikes 
but they had no sense of danger, and none were able to cross 
the street safely on their own or manage money (Clayton-
Smith 2001). Three adults in this group had a professional 
activity (delivering newspapers, cleaning, and helping in a 
shop), which they carried out under constant supervision. 
The main problems appear to be difﬁ  culties in remaining 
focused on an activity and impaired recognition of danger. 
The latter may occasionally be fatal (Ishmael et al 2002). 
Management with training procedures may be effective for 
developing adaptive skills (Didden et al 2001).
In contrast with weakness in motor-related skills, patients 
with Angelman syndrome show a signiﬁ  cant strength in 
socialization (Peters et al 2004b) that is based on nonverbal 
interactions (Williams et al 2006). This has been hypoth-
esized to be related to happy demeanor (Walz and Benson 
2002). However, these authors found that patients with 
Angelman syndrome did not show higher adaptive social 
skills than those with nonspeciﬁ  c mental retardation, and 
signiﬁ  cantly less than patients with Down syndrome or 
Prader-Willi syndrome (Walz and Benson 2002). In general, 
young adults are described as ﬁ  tting well into their local com-
munities and as being very sociable (Clayton-Smith 2001). 
It must be noted that participation in life events and society 
at large, a dimension that has increasingly been emphasized 
with respect to disability, is often limited by a form of cultural 
prescription. The latter may be overcome at many levels. 
Efforts to increase participation of patients with Angelman 
syndrome or other disabling conditions should not be less 
directed at changing environmental factors than at improv-
ing adaptive skills.
Eating disorders
In addition to nonfood-related oral behaviors, a variety 
of eating problems may occur (Clarke and Marston 2000; 
Williams et al 2006). Increased appetite and behavioral 
orientation to food affect about a third of patients (Barry 
et al 2005). These abnormal food behaviors (which are 
typical of Prader-Willi syndrome) may also lead to obesity 
(Clayton-Smith 2001). Intensive behavioral approaches may 
be necessary, including low-calorie diet, a regular exercise 
regimen, strict enforcement of limits, and constant super-
vision. Another common food-related problem is marked 
preference for certain foods, particularly those that do not 
require much chewing, such as bread, pasta, or banana. 
Counseling of carers about nutrition and oral function may 
be helpful. As food preference is a learned behavior, it can 
be altered by education.Neuropsychiatric Disease and Treatment 2008:4(3) 583
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Conclusion
The behavioral phenotype of Angelman syndrome has been 
increasingly better characterized over the last few decades. 
Apparent happiness is the hallmark of the syndrome, asso-
ciated with profuse smiling, poorly speciﬁ  c laughing and 
general exuberance, with hypermotor behavior, stereotypies, 
and proactive social contact. However, behavioral adapta-
tion is reduced and this seemingly happy demeanor may be 
deceptive, in particular with regard to anxiety. Prevalence 
of autistic disorder is still debated, possibly in relation to 
discrepancies in interpretation of autistic-like features. 
Research on animal models has already yielded valuable 
insights into other features of Angelman syndrome, includ-
ing some areas of cognition, motor control, epilepsy, sleep, 
and electrophysiology (Jiang et al 1998; Delorey et al 1998; 
Miura et al 2002; Weeber et al 2003; Cheron et al 2005, 2008; 
Colas et al 2005; Handforth et al 2005; van Woerden et al 
2007; Ferguson et al 2007). More speciﬁ  c study of behavior 
is still needed. In addition, the study of these behavioral 
aspects poses speciﬁ  c problems, some of which can only be 
addressed by studying the patients directly. This should be 
performed using approaches designed to decipher the com-
plexity of human behavior in the setting of severe intellectual 
disability (Horsler and Oliver 2006b). Currently, manage-
ment of problematic behaviors in patients with Angelman 
syndrome is primarily based on behavioral approaches, but 
psychoactive medication (eg, neuroleptics or antidepressants) 
may be required. Coping strategies of caregivers often need 
to be reinforced by counseling.
References
Angelman H. 1965. ‘Puppet’ children: A report on three cases. Dev Med 
Child Neurol, 7:681–8.
Artigas-Pallarés J, Brun-Gasca C, Gabau-Vila E, Guitart-Feliubadaló M, 
Camprubí-Sánchez C. 2005. Aspectos médicos y conductuales del 
síndrome de Angelman. Rev Neurol (Madrid) 41:649–56.
Barry RJ, Leitner RP, Clarke AR, et al. 2005. Behavioral aspects of Angel-
man syndrome: a case control study. Am J Med Genet 132:8–12.
Berg JM, Pakula Z. 1972. Angelman’s ("happy puppet") syndrome. Am J 
Dis Child, 123:72–4.
Bonati MT, Russo S, Finelli P, et al. 2007. Evaluation of autism traits in 
Angelman syndrome: a resource to unfold autism genes. Neurogenet-
ics, 8:169–78.
Bottani A, Robinson WP, DeLozier-Blanchet CD, et al. 1994. Angelman 
syndrome due to parental uniparental disomy of chromosome 15: a 
milder phenotype? Am J Med Genet, 51:35–40.
Buckley RH, Dinno N, Weber P. 1998. Angelman syndrome: are the esti-
mates too low? Am J Med Genet, 80:385–90.
Buntinx IM, Hennekam RCM, Brouwer OF, et al. 1995. Clinical pro-
ﬁ  le of Angelman syndrome at different ages. Am J Med Genet, 
56:176–83.
Bürger J, Kunze J, Sperling K, et al. 1996. Phenotypic differences in Angel-
man syndrome patients: imprinting mutations show less frequently 
microcephaly and hypopigmentation than deletions. Am J Med Genet, 
66:221–6.
Cassidy SB, Dykens E, Williams CA. 2000. Prader-Willi and Angelman 
Syndromes: sister imprinted disorders. Am J Med Genet, 97:136–46.
Cheron G, Servais L, Wagstaff J, et al. 2005. Fast cerebellar oscillation 
associated with ataxia in a mouse model of Angelman syndrome. 
Neuroscience, 130:631–7.
Cheron G, Servais L, Dan B. 2008. Cerebellar network plasticity: from 
genes to fast oscillation. Neuroscience, in press.
Clarke DJ, Marston G. Problem behaviors associated with 15q- Angelman 
syndrome. 2000. Am J Ment Retard, 105:25–31.
Clayton-Smith J. 1992. Angelman’s syndrome. Arch Dis Child, 67:889–91.
Clayton-Smith J. 1993. Clinical research on Angelman syndrome in the 
United Kingdom: observations on 82 affected individuals. Am J Med 
Genet, 46:12–15.
Clayton-Smith J. 2001. Angelman syndrome: evolution of the phenotype in 
adolescents and adults. Dev Med Child Neurol, 43:476–80.
Cohen D, Pichard N, Tordjman S, et al. 2005. Speciﬁ  c genetic disorders 
and autism: clinical contribution towards their identiﬁ  cation, J Autism 
Dev Disord, 35:103–16.
Colas D, Wagstaff J, Fort P, et al. 2005. Sleep disturbances in Ube3a 
maternal-deﬁ  cient mice modeling Angelman syndrome. Neurobiol 
Dis, 20:471–48.
Dan B, Boyd SG. 2003. Angelman syndrome reviewed from a neurophysi-
ological perspective. The UBE3A-GABRB3 hypothesis. Neuropediat-
rics, 34:169–76.
Dan B, Boyd SG. 2005. Nonconvulsive (dialeptic) status epilepticus in 
children. Curr Pediatr Rev, 1:7–16.
Dan B, Cheron G. 2003. Le syndrome d’Angelman syndrome: un modèle 
clinique et génétique. Rev Neurol (Paris), 159:499–510.
Dan B, Bouillot E, Bengoetxea A, et al. 2001. Distinct multi-joint control 
strategies in spastic diplegia associated with prematurity or Angelman 
syndrome. Clin Neurophysiol, 112:1618–25.
Dan B, Boyd SG, Cheron G. 2004a. From genomic imprinting to devel-
opmental physiology: identifying stepping stones. Curr Pharmacoge-
nomics, 2:232–43.
Dan B, Servais L, Boyd SG, et al. 2004b. From electrophysiology to chro-
matin: a bottom-up approach to Angelman syndrome. Ann N Y Acad 
Sci, 1030:599–611.
DeLorey TM, Handforth A, Anagnostaras SG, et al. 1998. Mice lacking 
the beta3 subunit of the GABAA receptor have the epilepsy phenotype 
and many of the behavioral characteristics of Angelman syndrome. 
J Neurosci, 18:8505–14.
Didden R, Sikkema SPE, Bosman ITM, et al. 2001. Use of a modiﬁ  ed 
Azrin-Foxx toilet training procedure with individuals with Angelman 
syndrome. J Appl Res Intellect Dis, 14:64–70.
Didden R, Korzilius H, Duker P, et al. 2004. Communicative functioning 
in individuals with Angelman syndrome: a comparative study. Disabil 
Rehabil, 26:1263–7.
Didden R, Korzilius H, Kamphuis A, et al. 2006. Preferences in individuals 
with Angelman syndrome assessed by a modiﬁ  ed Choice Assessment 
Scale. J Intellect Disabil Res, 50:54–60.
Dooley JM, Berg JM, Pakula Z, et al. 1981. The puppet-like syndrome of 
Angelman. Am J Dis Child, 135:621–4.
Dykens E. 1995. Measuring behavioral phenotypes: provocations from the 
‘New Genetics’. Am J Med Genet, 99:522–32.
Elian M. 1975. Fourteen happy puppets. Clin Pediatr (Phila), 14:902–8.
Ferguson C, Hardy SL, Werner DF, et al. 2007. New insight into the role 
of the beta3 subunit of the GABAA-R in development, behavior, body 
weight regulation, and anesthesia revealed by conditional gene knock-
out. BMC Neurosci, 8:85.
Fryburg JS, Breg WR, Lindgren V. 1991. Diagnosis of Angelman syndrome 
in infants. Am J Med Genet, 38:58–64.
Handforth A, Delorey TM, Homanics GE, et al. 2005. Pharmacologic 
evidence for abnormal thalamocortical functioning in GABA receptor 
β3 subunit-deﬁ  cient mice, a model of Angelman syndrome. Epilepsia, 
46:1860–70.
Horsler K, Oliver C. 2006a. Environmental inﬂ  uences on the behavioral 
phenotype of Angelman syndrome. Am J Ment Retard, 111:311–21.Neuropsychiatric Disease and Treatment 2008:4(3) 584
Pelc et al
Horsler K, Oliver C. 2006b. The behavioural phenotype of Angelman 
syndrome. J Intellect Disabil Res, 50:33–53.
Hou JW, Wang PJ, Wang TR. 1997. Angelman syndrome assessed by 
neurological and molecular cytogenetic investigations. Pediatr Neurol, 
16:17–22.
Ishmael HA, Begleiter ML, Butler MG. 2002. Drowning as a cause of death 
in Angelman syndrome. Am J Ment Retard, 107:69–70.
Jiang YH, Armstrong D, Albrecht U, et al. 1998. Mutation of the Angelman 
ubiquitin ligase in mice causes increased cytoplasmic p53 and deﬁ  cits of 
contextual learning and long-term potentiation. Neuron, 21:799–811.
Jolleff N, Ryan M. 1993. Communication development in Angelman’s 
syndrome. Arch Dis Child, 69:148–58.
Jolleff N, Emmerson F, Ryan M, et al. 2006. Communication skills in 
Angelman syndrome: Matching phenotype to genotype. Adv Speech 
Lang Pathology, 8:28–33.
Kibel MA, Burness FR. 1973. The ‘Happy Puppet’ syndrome. Centr Afr 
J Med, 19:91–3.
Kishino T, Lalande M, Wagstaff J. 1997. UBE3A/E6-AP mutations cause 
Angelman syndrome. Nat Genet, 15:70–3.
Knoll JH, Nicholls RD, Magenis RE, et al. 1989. Angelman and Prader-
Willi syndromes share a common chromosome 15 deletion but differ 
in parental origin of the deletion. Am J Med Genet, 32:285–90.
Laan LAEM, den Boer ATH, Hennekam RCM, et al. 1996. Angelman 
syndrome in adulthood. Am J Med Genet, 66:356–60.
Lossie AC, Whitney MM, Amidon D, et al. 2001. Distinct phenotypes 
distinguish the molecular classes of Angelman syndrome. J Med 
Genet, 38:834–45.
Magenis RE, Brown MG, Lacy DA, et al. 1987. Is Angelman syndrome an 
alternate result of del(15)(q11q13)? Am J Med Genet, 28:829–38.
Mahone EM, Bridges D, Prahme C, et al. 2004. Repetitive arm and hand 
movements (complex motor stereotypies) in children. J Pediatr, 
145:391–5.
Matsuura T, Sutcliffe JS, Fang P, et al. 2007. De novo truncating muta-
tions in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman 
syndrome. Nat Genet, 15:74–7.
Hersh JH, Bloom AS, Zimmerman AW, et al. 1981. Behavioral correlates 
in the happy puppet syndrome: a characteristic proﬁ  le? Dev Med Child 
Neurol, 23:792–800.
Galván-Manso M, Campistol J, Monros E, et al. 2002. Síndrome de Angel-
man: características físicas y fenotipo conductual en 37 pacientes con 
diagnóstico genético conﬁ  rmado. Rev Neurol (Madrid), 35:425–9.
McMahon W. 1999. Advances in the cognitive neuroscience of neurodevel-
opmental disorders: Views from child psychiatry and medical genetics. 
In: Tager-Flusberg H (ed). Neurodevelopmental Disorders. Cambridge, 
MA: MIT Pr, pp. 583–600.
Miura K, Kishino T, Li E, et al. 2002. Neurobehavioral and electroencepha-
lographic abnormalities in Ube3a maternal-deﬁ  cient mice. Neurobiol 
Dis, 9:149–59.
Moncla A, Malzac P, Voelckel MA, et al. 1999. Phenotype-genotype cor-
relation in 20 deletion and 20 nondeletion Angelman syndrome patients. 
Eur J Hum Genet, 7:131–9.
O’Brien G, Yule W. 1995. Behavioural Phenotypes. London: Mac Keith 
Press.
Oliver C, Demeetriades L, Hall S. 2002. Effects of environmental events 
on smiling and laughing behavior in Angelman syndrome. Am J Ment 
Retard, 107:194–200.
Pelc K, Dan B. 2008. The ADHD Tetragrammaton taken in vain in neuro-
genetic disorders? Acta Paediatr, 1:2–4.
Pelc K, Boyd SG, Cheron G, et al. 2008a. Epilepsy in Angelman syndrome. 
Seizure, in press.
Pelc K, Cheron G, Boyd SG, et al. 2008b. Are there distinctive sleep prob-
lems in Angelman syndrome? Sleep Med, in press.
Penner KA, Johnston J, Faircloth BH, et al. 1993. Communication, cogni-
tion and social interaction in the Angelman Syndrome. Am J Med 
Genet, 46:34–9.
Peters SU, Beaudet AL, Madduri N, et al. 2004a. Autism in Angelman’s 
syndrome: implications for autism research. Clin Genet, 66:530–6.
Peters SU, Goddard-Finegold J, Beaudet AL, et al. 2004b. Cognitive and 
adaptive behavior proﬁ  les of children with Angelman syndrome. 
Am J Med Genet, 128:110–13.
Philippart M, Minassian BA. 2005. Angelman syndrome from infancy to 
old age [abstract]. Am J Hum Genet, 79(Suppl):605.
Pulsifer MB. 1996. The neuropsychology of mental retardation. J Int Neu-
ropsychol Soc, 2:159–76.
Richman DM, Gernat E, Teichman H. 2006. Effects of social stimuli on 
laughing and smiling in young children with Angelman syndrome. 
Am J Ment Retard, 111:442–6.
Robb SA, Pohl KRE, Baraister M, et al. 1989. The ‘happy puppet’ syn-
drome of Angelman: review of the clinical features. Arch Dis Child, 
64:83–6.
Saitoh S, Harada N, Jinno Y, et al. 1994. Molecular and clinical study of 61 
Angelman syndrome patients. Am J Med Genet, 52:158–63.
Smith A, Wiles C, Haan E, et al. 1996. Clinical features in 27 patients with 
Angelman syndrome resulting from DNA deletion. J Med Genet, 
33:107–12.
Steffenburg S, Gillberg CL, Steffenburg U, et al. 1996. Autism in Angelman 
syndrome: a population-based study. Pediatr Neurol, 14:131–6.
Summers JA, Feldman MA. 1999. Distinctive pattern of behavioural func-
tioning in Angelman syndrome. Am J Ment Retard, 104:376–84.
Summers JA, Allison DB, Lynch PS, et al. 1995. Behaviour problems in 
Angelman syndrome. J Intellect Disabil Res, 39:97–106.
Thelen E. 1979. Rhythmical stereotypies in normal human infants. Animal 
Behav, 27:699–715.
Thompson RJ, Bolton PF. 2003. Case report: Angelman syndrome in an 
individual with a small SMC(15) and paternal uniparental disomy: a 
case report with reference to the assessment of cognitive functioning 
and autistic symptomatology. J Autism Dev Disord, 33:171–6.
Trillingsgaard A, Østergaard JR. 2004. Autism in Angelman syndrome: An 
exploration of comorbidity. Autism, 8:163–74.
Vanagt WY, Pulles-Heintzberger CF, Vernooy K, et al. 2005. Asystole 
during outbursts of laughing in a child with Angelman syndrome. 
Pediatr Cardiol, 26:866–8.
van Woerden GM, Harris KD, Hojjati MR, et al. 2007. Rescue of neu-
rological deﬁ  cits in a mouse model for Angelman syndrome by 
reduction of alphaCaMKII inhibitory phosphorylation. Nat Neurosci, 
10:280–2.
Veltman MWM, Craig EE, Bolton P. 2005. Autism spectrum disorders in 
Prader-Willi and Angelman syndromes: a systematic review. Psychi-
atric Genetics, 15:243–54.
Walz NC. 2006. Parent report of stereotyped behaviors, social interaction, 
and developmental disturbances in individuals with Angelman syn-
drome. J Autism Dev Disord, 37:940–7.
Walz NC, Baranek GT. 2006. Sensory processing patterns in persons with 
Angelman syndrome. Am J Occup Ther, 60:472–9.
Walz NC, Benson BA. 2002. Behavioral phenotypes in children with Down 
syndrome, Prader-Willi syndrome, and Angelman syndrome. J Dev 
Phys Disabil, 14:307–21.
Weeber EJ, Jiang YH, Elgersma Y, et al. 2003. Derangements of hippo-
campal calcium/calmodulin-dependent protein kinase II in a mouse 
model for Angelman mental retardation syndrome. J Neurosci, 
23:2634–44.
Williams CA, Frias JL. 1982. The Angelman (“happy puppet”) syndrome. 
Am J Med Genet, 11:453–60.
Williams CA, Lossie A, Driscoll D, et al. 2001. Angelman syndrome: mim-
icking conditions and phenotypes. Am J Med Genet, 101:59–64.
Williams CA, Beaudet AL, Clayton-Smith J, et al. 2006. Angelman syn-
drome 2005: updated consensus for diagnostic criteria. Am J Med 
Genet, 140:413–18.
Zori RT, Hendrickson J, Woolven S, et al. 1992. Angelman syndrome: 
clinical proﬁ  le. J Child Neurol, 7:270–80.